if zoptEC passes the stock should climb into a range between $4 - $11 depending on market cap expectations just based on zoptEC alone
phase 3 is all I need to know and .08 cents ain't bad, don't over think it be a gun slinger, where's the spirit don't be a wuss, good luck
Unfortunately it seems Mr Dodd has zero integrity, his reverse split to $5 will give them room to dilute shareholder back down to .05 cents
I would guess no, so AEZS is going to be the first. Going down with the ship lol
Ok so I'll do worst case Noid's math 721M share outstanding and I'll go with JAZZ Pharma market cap of let's say 8B, so the best we could hope for is....$11 stock if zoptEC passes. I'll take that right now
Do warrant holders control more than 50% of the stock, was Turpin removed by the new owners? Did the warrant deal turn into a stealth buyout. Who owns the majority of the shares now?
Not bad for a .09 cent stock with cash and no debt. I'm starting to think Dodd has a game plan.
L.EO. would be just fine with me. Hey you noticed there's no bloggers coming out of the woodwork to dis zoptEC as we had in the run up to Perifosine failure.
That's the only positive from this trial is that news has not leaked out about the trial. You don't have experts such as Adam F. trying to build their reputation, big concern is the market cap of AEZS shows weakness ahead of final results
agree, some big money out there seems to think so. Also on unrelated news Apple moved up it's delivery date of it's electric car to 2019
zoptEC is the only phase 3 cancer drug, AEZS-130 is a growth hormone test kit only and with 1 rejection the odds don't look good. Not sure of your 2 other phase 3, who is doing the testing? What drug, can you provide data?
Maybe after a few more dog and pony conferences to NY City staying at the Waldorf. Maybe he can do another reverse split, issue shares for a new dream drug, that should be good until 2020